Last reviewed · How we verify
ENDOSTAR，cisplatin
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors.
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors. Used for Non-small cell lung cancer (in combination with cisplatin), Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | ENDOSTAR，cisplatin |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Angiogenesis inhibitor |
| Target | Endothelial cells; inhibits VEGF-mediated angiogenesis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Endostar (rh-endostatin) is an angiogenesis inhibitor derived from the C-terminal fragment of collagen XVIII. It suppresses tumor neovascularization by inhibiting endothelial cell proliferation and migration, thereby starving tumors of blood supply. When combined with cisplatin, a platinum-based chemotherapy agent that causes DNA damage, the dual mechanism targets both tumor vasculature and cancer cells directly.
Approved indications
- Non-small cell lung cancer (in combination with cisplatin)
- Advanced solid tumors (Phase 3 development)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Nephrotoxicity
- Peripheral neuropathy
- Bleeding
Key clinical trials
- A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions (PHASE3)
- Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma (PHASE1, PHASE2)
- Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (PHASE2)
- Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (PHASE2)
- Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
- First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial (PHASE2)
- Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial (PHASE2)
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENDOSTAR，cisplatin CI brief — competitive landscape report
- ENDOSTAR，cisplatin updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI